Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Haleon PLC ( (GB:HLN) ) is now available.
Haleon PLC has announced the purchase and cancellation of over one million of its own shares as part of a share buyback program initiated in March 2025. This move is likely to impact the company’s share capital structure, reducing the number of shares with voting rights, which may influence shareholder notifications under regulatory guidelines.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.
Haleon PLC’s overall stock score reflects a strong financial foundation and strategic initiatives like share buybacks contributing positively to shareholder value. However, technical indicators suggest bearish trends, and the relatively high P/E ratio raises valuation concerns. The company’s confidence in its growth outlook, despite some market challenges, provides additional strength to its stock position.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a portfolio that includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 26,495,665
Technical Sentiment Signal: Buy
Current Market Cap: £34.61B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.